Bank of America
VERV

Bank of America’s Verve Therapeutics VERV Stock Holding History

Bank of America’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-485,803
Closed -$5.46M – 8706
2025
Q2 		$5.46M Sell
485,803
-1,147,073
-70% -$6.54M ﹤0.01% 3805
2025
Q1 		$7.46M Buy
1,632,876
+1,085,205
+198% +$7.27M ﹤0.01% 3439
2024
Q4 		$3.09M Sell
547,671
-228,551
-29% -$1.29M ﹤0.01% 4059
2024
Q3 		$3.76M Buy
776,222
+303,206
+64% +$1.76M ﹤0.01% 3998
2024
Q2 		$2.31M Buy
473,016
+99,792
+27% +$627K ﹤0.01% 4336
2024
Q1 		$4.96M Buy
373,224
+135,351
+57% +$1.79M ﹤0.01% 3618
2023
Q4 		$3.32M Sell
237,873
-76,899
-24% -$953K ﹤0.01% 3912
2023
Q3 		$4.17M Buy
314,772
+141,905
+82% +$2.29M ﹤0.01% 3574
2023
Q2 		$3.24M Sell
172,867
-211,839
-55% -$3.53M ﹤0.01% 3787
2023
Q1 		$5.55M Sell
384,706
-20,687
-5% -$405K ﹤0.01% 3445
2022
Q4 		$7.84M Buy
405,393
+261,198
+181% +$6.92M ﹤0.01% 2917
2022
Q3 		$4.95M Buy
144,195
+125,406
+667% +$4M ﹤0.01% 3364
2022
Q2 		$287K Sell
18,789
-192,605
-91% -$2.98M ﹤0.01% 5841
2022
Q1 		$4.82M Buy
211,394
+160,544
+316% +$4.59M ﹤0.01% 3672
2021
Q4 		$1.88M Buy
50,850
+48,594
+2,154% +$2.04M ﹤0.01% 4626
2021
Q3 		$106K Buy
2,256
+1,884
+506% +$111K ﹤0.01% 6692
2021
Q2 		$22K Buy
+372
New +$15.4K ﹤0.01% 7110

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America's VERV Position: Q3 2025 in Review

Bank of America sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 485,803 shares — an estimated $5.46M sold.

Bank of America first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $7.84M in Q4 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Bank of America reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bank of America sold 485,803 Verve Therapeutics shares in Q3 2025, an estimated $5.46M.
  • Bank of America first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Bank of America's Verve Therapeutics position peaked at $7.84M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.